Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: West Pharmaceutical Services (WST), Blueprint Medicines (BPMC) and Vera Therapeutics (VERA)

Tipranks - Tipranks - Wed Jun 4, 2025

Analysts have been eager to weigh in on the Healthcare sector with new ratings on West Pharmaceutical Services (WST – Research Report), Blueprint Medicines (BPMC – Research Report) and Vera Therapeutics (VERA – Research Report).

Confident Investing Starts Here:

West Pharmaceutical Services (WST)

In a report released today, Nico Chen from DBS maintained a Buy rating on West Pharmaceutical Services, with a price target of $265.00. The company’s shares closed last Monday at $209.39, close to its 52-week low of $197.01.

According to TipRanks.com, Chen is a 3-star analyst with an average return of 2.4% and a 46.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Siemens Healthineers AG, and Johnson & Johnson. ;'>

West Pharmaceutical Services has an analyst consensus of Strong Buy, with a price target consensus of $276.25, a 32.9% upside from current levels. In a report issued on May 22, Citi also maintained a Buy rating on the stock with a $300.00 price target.

See today’s best-performing stocks on TipRanks >>

Blueprint Medicines (BPMC)

Barclays analyst Peter Lawson maintained a Hold rating on Blueprint Medicines today and set a price target of $105.00. The company’s shares closed last Monday at $127.79.

According to TipRanks.com, Lawson is ranked 0 out of 5 stars with an average return of -9.4% and a 37.4% success rate. Lawson covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Springworks Therapeutics, and Iovance Biotherapeutics. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for Blueprint Medicines with a $120.23 average price target, which is a -6.1% downside from current levels. In a report released yesterday, Wedbush also downgraded the stock to Hold with a $129.00 price target.

Vera Therapeutics (VERA)

Wells Fargo analyst Mohit Bansal assigned a Buy rating to Vera Therapeutics yesterday and set a price target of $70.00. The company’s shares closed last Monday at $31.74.

According to TipRanks.com, Bansal is a 4-star analyst with an average return of 3.2% and a 51.2% success rate. Bansal covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., Vertex Pharmaceuticals, and Travere Therapeutics. ;'>

Currently, the analyst consensus on Vera Therapeutics is a Strong Buy with an average price target of $68.40, which is an 115.5% upside from current levels. In a report issued on May 23, LifeSci Capital also maintained a Buy rating on the stock with a $70.00 price target.

Read More on WST:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).